Drug intelligence / Profile preview

autologous bone marrow cell concentrate + platelet-rich plasma gel

Development stage
Unknown
Modality
Stem Cell Therapies → Cell Therapies
Administration
Local Injection (intra-articular, Peri-tendinous, Or Intra-lesional)
01

Overview

A combination of **autologous bone marrow cell concentrate** (BMAC) and **platelet-rich plasma (PRP) gel** is a regenerative cell therapy used to promote tissue repair and healing by harnessing the synergistic effects of stem and progenitor cells from bone marrow and growth factors from activated platelets. - **Bone marrow cell concentrate** is obtained by aspirating bone marrow from the patient, processing it to concentrate stem and progenitor cells, and then re-injecting these cells at the site of injury. BMAC contains mesenchymal stem cells (MSCs), hematopoietic stem cells, and accessory cells that aid in tissue regeneration through differentiation, paracrine signaling, immunomodulation, and stimulation of local repair processes. - **Platelet-rich plasma gel** is prepared by centrifuging the patient’s blood to concentrate platelets, then activating them (often with calcium chloride or thrombin) to form a gel that releases a cocktail of growth factors (including PDGF, VEGF, TGF-β, IGF, and FGF) crucial for cell migration, proliferation, angiogenesis, and tissue regeneration[1][2][3][4][5][7]. - When combined, BMAC provides a source of reparative cells, while PRP gel delivers growth factors that stimulate these cells and accelerate healing. This therapy is primarily used in orthopedics and sports medicine to treat joint, tendon, ligament, bone, and cartilage injuries resistant to conventional therapies. - BMAC + PRP gel is **autologous** (sourced from the same patient), reducing risks of immune reaction and disease transmission. - The mechanism of action is multifactorial: direct engraftment and differentiation of mesenchymal stem/progenitor cells; paracrine release of immunomodulatory and regenerative signals; and amplification of wound healing cascades via PRP-derived growth factors.

Other names
autologous BMAC + PRP gelbone marrow aspirate concentrate + PRP gelautologous cell concentrate + PRP gel

Beyond the preview

Go deeper on autologous bone marrow cell concentrate + platelet-rich plasma gel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on autologous bone marrow cell concentrate + platelet-rich plasma gel.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call